Breaking Down Selecta Biosciences, Inc. (SELB) Financial Health: Key Insights for Investors

Selecta Biosciences, Inc. (SELB) stands at the intersection of immunology and precision medicine, developing targeted antigen-specific immune therapies using its proprietary ImmTOR™ platform to improve the safety and efficacy of biologics for rare and serious diseases; the company is a clinical-stage biotech headquartered in Watertown, Massachusetts, operates a state-of-the-art GMP manufacturing facility, and advances a pipeline that includes candidates for chronic refractory gout, autoimmune diseases, and rare inborn errors of metabolism-while forging strategic collaborations with industry leaders such as AskBio to push its gene therapy initiatives forward; investors and clinicians alike are watching as SELB shares trade at $8.97 per share as of December 16, 2025, and the company's focused platform approach and manufacturing capabilities position it to address unmet needs across multiple indications, making the full article essential reading for anyone tracking translational immunotherapies and the evolving biotech landscape

Selecta Biosciences, Inc. (SELB) - Intro

• Core technology: ImmTOR™ - nanoparticle-based tolerogenic platform designed to mitigate anti-drug immune responses and enable repeat dosing of biologics and gene therapies.
• Therapeutic focus areas: chronic refractory gout, autoimmune diseases, and rare inborn errors of metabolism.
• Strategic partnerships: includes AskBio (AAV gene therapy programs) and other industry collaborators for co-development and platform application.

Mission

Vision

Core Values

• Scientific Rigor - commitment to hypothesis-driven development, reproducibility, and rigorous clinical evaluation.
• Patient Focus - designing programs and end points that prioritize meaningful clinical benefit and safety for patients with high unmet need.
• Collaboration - partnering with academic, industry, and regulatory stakeholders to accelerate translation and access.
• Manufacturing Excellence - investing in GMP capabilities to ensure quality, scale readiness, and control over critical material supply.
• Integrity & Transparency - ethical conduct in trials, reporting, and stakeholder communications.

Selecta Biosciences, Inc. (SELB) - Overview

• Mission: Develop therapies that enable durable, antigen-specific immune tolerance to transform the safety and long-term efficacy of biologic medicines.
• Vision: Become a leader in precision immune modulation, enabling lifecycle control of biologics and gene therapies across rare and common diseases.
• Core values:
  • Patient-centered innovation
  • Scientific rigor and translational excellence
  • Collaborative partnerships
  • Operational quality and compliance

• Modular ImmTOR™ platform designed to enable antigen-specific tolerance and to reduce immunogenicity of biologics and gene therapies.
• Key therapeutic areas: chronic refractory gout, autoimmune diseases, and rare inborn errors of metabolism.
• Partnerships: strategic collaborations with industry leaders, including AskBio, to integrate ImmTOR with gene therapy platforms and advance clinical programs.

Selecta Biosciences, Inc. (SELB): Mission Statement

• Clinical-stage biotechnology company headquartered in Watertown, Massachusetts.
• Proprietary ImmTOR™ platform designed to induce antigen-specific immune tolerance and enhance biologic delivery.
• Pipeline focuses on chronic refractory gout, autoimmune diseases, and rare inborn errors of metabolism.
• Operates a state-of-the-art GMP manufacturing facility supporting clinical and early commercial needs.
• Strategic collaborations with industry partners such as AskBio to advance gene therapy programs.

• Drive targeted immune tolerance solutions that enable safer, more effective biologic and gene therapies for patients with high unmet medical needs.
• Translate ImmTOR science into commercial-ready products and durable therapeutic partnerships.

• Be the leading enabler of antigen-specific immune modulation across biologics and gene therapy, transforming treatment paradigms for rare and refractory diseases.
• Create durable, scalable manufacturing and clinical development pathways to bring safer therapies to patients globally.

• Science-driven innovation - prioritize rigorous translational research and data-driven decision making.
• Patient-centricity - focus on meaningful clinical benefit and safety for patients with limited treatment options.
• Collaboration - build strategic partnerships to accelerate development and broaden therapeutic reach.
• Operational excellence - maintain high-quality GMP manufacturing and clinical operations to support development milestones.
• Integrity and transparency - ethical conduct in research, collaboration, and investor communications.

• ImmTOR-enabled biologics: programs targeting anti-drug antibody (ADA) prevention to extend efficacy of enzyme replacement and biologic therapies.
• Gout program: development candidate(s) aimed at chronic refractory gout to reduce gout flares and to improve patient outcomes.
• Autoimmunity and rare disease programs: antigen-specific tolerance approaches to modulate pathogenic immune responses in selected indications.
• Gene therapy enablement: partnerships (e.g., AskBio) to combine ImmTOR with AAV-based gene therapies to reduce capsid- and transgene-directed immune responses.

Selecta Biosciences, Inc. (SELB) - Vision Statement

• Patient‑centricity: prioritize measures that materially improve patient safety and quality of life.
• Scientific rigor: commit to robust, translational science and reproducible clinical evidence.
• Collaboration: pursue strategic partnerships that accelerate development and broaden impact.
• Integrity: maintain transparent governance, ethical clinical conduct, and stewardship of resources.
• Innovation: continuously advance platform technologies to address new therapeutic opportunities.

• Headquarters and manufacturing: Watertown, MA - with a GMP manufacturing suite to support clinical supply and accelerate translational timelines.
• Strategic alliances: collaboration with AskBio to apply ImmTOR for AAV‑based gene therapies, aiming to reduce immune barriers to repeat dosing and broaden patient eligibility.
• Clinical focus: portfolio concentrated on indications where anti‑drug immunity limits efficacy or safety (e.g., refractory gout, enzyme replacement, gene therapy applications).
• Public market presence: trading ticker SELB - share price reported at $8.97 per share as of December 16, 2025.

• Partnerships de‑risk platform expansion: collaborations with established gene therapy players (e.g., AskBio) extend ImmTOR's application to AAV programs and create shared development pathways.
• Capital and runway considerations: as a clinical‑stage company, capital allocation is directed primarily to R&D, GMP supply, and strategic partnerships to progress select programs to pivotal stages.